Senior Director, Clinical Sciences, Ultragenyx
Dr. Skrinar has served as the Senior Director, Clinical Sciences since March 2012. Prior to joining Ultragenyx, Ms. Skrinar worked as the Senior Director of Clinical Outcomes and Regulatory Affairs at Enobia Pharma, Inc., a private clinical stage orphan company acquired by Alexion in 2012 focused on the development of an enzyme replacement therapy for hypophosphastasia. Previously, as the Senior Director of Clinical Outcomes at Genzyme Corporation, she led the design and implementation of clinical trials of Myozyme/Lumizyme, an enzyme replacement therapy for Pompe disease and participated in the clinical development program for Aldurazyme, an enzyme replacement therapy for the treatment of MPS 1. In her nearly 15 years in biotech, Ms. Skrinar has worked exclusively on the clinical development and regulatory approval of ultra-orphan drugs. Ms. Skrinar received a BBA from Emory University and a Ph.D. and MPH from the University of Alabama.